The Department of Veterans Affairs (VA) National Acquisition Center is preparing to issue Request for Proposal (RFP) 36E79725R0023 for Fludrocortisone Acetate 0.1MG Tablets, supplied in bottles of 100 tablets. This procurement aims to ensure an uninterrupted supply of the drug for various federal entities, including the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). A single contract will be awarded, covering an initial year with four optional renewal periods. The solicitation will be published on or around March 28, 2025, with submissions due by April 11, 2025. Potential suppliers must provide specific product identifiers, such as a unique NDC or UPC number and the name as it appears on the product label. Interested parties are encouraged to monitor the provided URL for any updates or amendments, as no paper copies will be issued. The estimated annual requirement for the tablets is 31,127 bottles. Youlanda Duggar serves as the point of contact for any inquiries regarding this solicitation.

The document outlines a federal solicitation (SF-1449) from the Department of Veterans Affairs for the procurement of Fludrocortisone Acetate 0.1 MG Tablets under the VA & DoD Pharmaceutical Prime Vendor Programs. It emphasizes the requirement for contractors to submit bids that include pricing for a base year and four option years, adhering to stipulated guidelines, including a 0.5% Cost Recovery Fee. The contracting process mandates compliance with regulations, including the Drug Supply Chain Security Act and the need for a unique National Drug Code (NDC) for each offered product. Moreover, it emphasizes the contractor's obligations related to product registration and adherence to Good Manufacturing Practices (cGMP) as enforced by the FDA. The proposal must clearly indicate manufacturing sources, and contractors must maintain stable agreements to ensure product availability. Any contractual backorders or recalls must be promptly reported, and the document details payment structures and reporting obligations for the contractors involved. This solicitation illustrates the government's commitment to ensuring consistent and reliable pharmaceutical supplies while promoting small business participation in government contracting.

This document is an amendment issued by the Department of Veterans Affairs to extend the deadline for submitting offers in response to solicitation 36E79725R0023 for Fludrocortisone Acetate Tablets. The original due date of April 14, 2025, has been extended to April 21, 2025, at 2:30 PM Central Daylight Time. All other terms and conditions of the solicitation remain unchanged. Offerors are instructed to include a signed copy of this amendment with their proposals. The amendment serves to ensure adequate opportunity for bidders to prepare their submissions while maintaining compliance with competitive procurement practices typical within government contracting, particularly in the context of federal RFP processes. Overall, this document reflects the administrative adjustments necessary in the solicitation timeline without altering the substantive requirements for proposals.